Jazz Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Jazz Pharmaceuticals PLC
JAZZ Stock  USD 139.51  0.71  0.51%   
Jazz Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Jazz Pharmaceuticals PLC investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Jazz Pharmaceuticals financial statements helps investors assess Jazz Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Jazz Pharmaceuticals' valuation are summarized below:
Gross Profit
3.8 B
Profit Margin
0.1377
Market Capitalization
8.5 B
Enterprise Value Revenue
2.8381
Revenue
4.1 B
We have found one hundred twenty available fundamental trends for Jazz Pharmaceuticals PLC, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to confirm all of Jazz Pharmaceuticals PLC regular market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road.

Jazz Pharmaceuticals Total Revenue

4.27 Billion

Check Jazz Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Jazz Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 250 M, Other Operating Expenses of 3.5 B or Operating Income of 752.5 M, as well as many indicators such as Price To Sales Ratio of 1.78, Dividend Yield of 0.0 or PTB Ratio of 1.77. Jazz financial statements analysis is a perfect complement when working with Jazz Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Jazz Pharmaceuticals Correlation against competitors.

Jazz Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding52.5 M66 M57.4 M
Slightly volatile
Total Assets12.6 B12 B6.1 B
Slightly volatile
Short and Long Term Debt Total66.4 M69.9 M1.9 B
Slightly volatile
Other Current Liabilities941 M896.2 M377.8 M
Slightly volatile
Total Current Liabilities1.1 B1 B514.9 M
Slightly volatile
Other Liabilities1.3 B1.2 B550.9 M
Slightly volatile
Property Plant And Equipment Net126.1 M227 M150.5 M
Slightly volatile
Accounts Payable81.8 M77.9 M44.3 M
Slightly volatile
Cash2.5 B2.4 B842.6 M
Slightly volatile
Non Current Assets Total7.8 B7.4 B4.3 B
Slightly volatile
Non Currrent Assets Other130.2 M124 M39.9 M
Slightly volatile
Other Assets136.8 M197.2 M166.7 M
Slightly volatile
Cash And Short Term Investments3.1 B3 B1.1 B
Slightly volatile
Net Receivables752.6 M716.8 M343.7 M
Slightly volatile
Good Will1.8 B1.7 B985.6 M
Slightly volatile
Liabilities And Stockholders Equity12.6 B12 B6.1 B
Slightly volatile
Non Current Liabilities Total7.2 B6.9 B3.2 B
Slightly volatile
Inventory504.5 M480.4 M236.6 M
Slightly volatile
Other Current Assets460.9 M439 M169.5 M
Slightly volatile
Other Stockholder Equity4.1 B3.9 B2.2 B
Slightly volatile
Total Liabilities8.3 B7.9 B3.7 B
Slightly volatile
Property Plant And Equipment Gross408.4 M389 M186.6 M
Slightly volatile
Total Current Assets4.9 B4.6 B1.8 B
Slightly volatile
Intangible Assets5 B4.8 B2.9 B
Slightly volatile
Property Plant Equipment363.9 M346.6 M168.9 M
Slightly volatile
Current Deferred Revenue140.2 M133.5 M26.4 M
Slightly volatile
Short Term Debt85.4 M45.8 M86.1 M
Slightly volatile
Common Stock5.7 K6 K46.9 K
Very volatile
Common Stock Total Equity5.1 K5.4 K51.2 K
Slightly volatile
Capital Surpluse2.2 B4 B2.1 B
Slightly volatile
Deferred Long Term Liabilities1.1 B1.1 B411.6 M
Slightly volatile
Long Term Debt Total6.9 B6.5 B2.7 B
Slightly volatile
Non Current Liabilities Other107.3 M86.6 M86.8 M
Slightly volatile
Deferred Long Term Asset Charges95.6 M141.3 M107.3 M
Slightly volatile
Short and Long Term Debt29.4 M31 M210.3 M
Slightly volatile
Net Invested Capital7.9 B10.2 B6 B
Slightly volatile
Long Term Investments4.9 M5.2 M3.5 M
Slightly volatile
Net Working Capital1.9 B3.6 B1.3 B
Slightly volatile
Capital Stock48.8 K54.9 K59.9 K
Slightly volatile
Capital Lease Obligations85.5 M53.7 M137.7 M
Slightly volatile

Jazz Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses3.5 B3.4 B1.6 B
Slightly volatile
Depreciation And Amortization771.2 M734.5 M307.5 M
Slightly volatile
Selling General Administrative1.5 B1.4 B744.7 M
Slightly volatile
Total Revenue4.3 B4.1 B2 B
Slightly volatile
Gross Profit4.3 B4.1 B1.9 B
Slightly volatile
Research Development232 M445.7 M262.1 M
Slightly volatile
Cost Of Revenue468 M445.7 M210.2 M
Slightly volatile
Non Recurring697.7 M664.5 M341.3 M
Slightly volatile
Interest Income81.7 M94.5 M72.1 M
Slightly volatile
Reconciled Depreciation480.8 M660.1 M320.8 M
Slightly volatile
Extraordinary Items6.4 K6.8 K77.6 M
Slightly volatile

Jazz Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow1.6 B1.5 B635.9 M
Slightly volatile
Depreciation693.1 M660.1 M295.6 M
Slightly volatile
Capital Expenditures45.7 M48.1 M122.9 M
Slightly volatile
End Period Cash Flow2.5 B2.4 B842.6 M
Slightly volatile
Stock Based Compensation260.4 M248 M121.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.781.87164.8433
Slightly volatile
Days Sales Outstanding42.2664.296556.7347
Slightly volatile
Stock Based Compensation To Revenue0.06920.0610.0617
Pretty Stable
Capex To Depreciation0.06920.07280.585
Pretty Stable
EV To Sales1.231.29585.443
Slightly volatile
Inventory Turnover0.80.842.2029
Slightly volatile
Days Of Inventory On Hand473450278
Slightly volatile
Payables Turnover3.13.824.0458
Pretty Stable
Sales General And Administrative To Revenue0.390.370.3434
Pretty Stable
Research And Ddevelopement To Revenue0.10.10950.2399
Slightly volatile
Capex To Revenue0.01120.01180.066
Pretty Stable
Cash Per Share50.8248.398518.0096
Slightly volatile
Days Payables Outstanding13299.02112
Slightly volatile
Intangibles To Total Assets0.470.53880.6109
Very volatile
Current Ratio2.484.45713.5152
Very volatile
Receivables Turnover7.995.67686.5144
Slightly volatile
Graham Number12211671.3726
Slightly volatile
Capex Per Share1.370.77742.1118
Slightly volatile
Revenue Per Share69.0965.800234.01
Slightly volatile
Interest Debt Per Share4.734.981333.9098
Slightly volatile
Debt To Assets0.00550.00580.3231
Pretty Stable
Operating Cycle61.0864.2965278
Slightly volatile
Days Of Payables Outstanding13299.02112
Slightly volatile
Quick Ratio2.293.99453.225
Pretty Stable
Net Income Per E B T0.871.19091.1001
Pretty Stable
Cash Ratio1.852.32321.8076
Pretty Stable
Days Of Inventory Outstanding473450278
Slightly volatile
Days Of Sales Outstanding42.2664.296556.7347
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.990.96560.8371
Very volatile
Fixed Asset Turnover17.0317.925330.3508
Slightly volatile
Debt Ratio0.00550.00580.3231
Pretty Stable
Price Sales Ratio1.781.87164.8433
Slightly volatile
Asset Turnover0.510.33870.3846
Pretty Stable
Gross Profit Margin0.710.80.8813
Slightly volatile

Jazz Fundamental Market Drivers

Forward Price Earnings5.963
Cash And Short Term Investments3 B

Jazz Upcoming Events

6th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Jazz Pharmaceuticals Financial Statements

Jazz Pharmaceuticals investors use historical fundamental indicators, such as Jazz Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Jazz Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue133.5 M140.2 M
Total Revenue4.1 B4.3 B
Cost Of Revenue445.7 M468 M
Stock Based Compensation To Revenue 0.06  0.07 
Sales General And Administrative To Revenue 0.37  0.39 
Research And Ddevelopement To Revenue 0.11  0.10 
Capex To Revenue 0.01  0.01 
Revenue Per Share 65.80  69.09 
Ebit Per Revenue 0.18  0.18 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CRMSalesforce
CRMSalesforce

Additional Tools for Jazz Stock Analysis

When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY